Pharma-Bio Serv, Inc.: management transactions · United States · SEC (Form 4)

About Pharma-Bio Serv, Inc.

Pharma-Bio Serv, Inc. (PBSV) is a U.S. small-cap company focused on regulatory compliance and life-sciences consulting services. The company was organized as a Delaware corporation on January 14, 2004, and is headquartered in Dorado, Puerto Rico. Its operating footprint spans Puerto Rico, the United States, Europe, and, to a lesser extent, Brazil. PBSV serves pharmaceutical, biotechnology, medical device, cosmetic, food, chemical, and allied-products companies, with services centered on regulatory affairs, quality systems, validation, project management, and technology transfer. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001304161/000165495426000710/pbsv_10k.htm)) From an equity-market perspective, an important clarification is that PBSV is quoted on the OTCQB market, not on the NYSE or NASDAQ. That makes it a niche microcap followed by a narrower investor base, including market participants who monitor SEC filings and insider activity closely. The company’s business model is service-oriented rather than asset-heavy: it monetizes technical expertise, client relationships, and regulatory know-how instead of manufacturing capacity or patented drug assets. In that sense, PBSV should be viewed as a specialized professional-services provider within the healthcare and life-sciences ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm?utm_source=openai)) PBSV’s competitive position rests on domain specialization and long-standing customer relationships. The company states that it has well-established ties with major pharmaceutical, biotechnology, medical device, and chemical manufacturers in Puerto Rico and the United States, which can provide cross-border commercial access. Its consulting teams include engineering and life-science professionals, former quality assurance managers and directors, and other experienced specialists. That mix supports a broad service offering that can cover compliance readiness, validation work, documentation support, and transfer-of-technology projects—capabilities that are particularly valuable when clients are navigating FDA requirements and international regulatory standards. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001304161/000165495426000710/pbsv_10k.htm)) Recent disclosures suggest a business that remains small but operationally steady. For the quarter ended January 31, 2026, the company reported revenue of about $2.3 million, slightly lower year over year, while net income improved to $32,860. In its fiscal 2025 annual report, PBSV described a solid liquidity position and outlined investments in technology, including an AI-based dashboard intended to automate business-development opportunities and support recruitment and placement. The company also referenced a shareholder dividend and an ongoing effort to strengthen its service portfolio and operating structure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1304161/000165495426002338/pbsv_ex991.htm?utm_source=openai)) For international equity investors, the key takeaway is that Pharma-Bio Serv is not a drug developer or a high-growth platform stock; it is a specialized compliance and technology-transfer consultant serving regulated industries across multiple geographies, with Puerto Rico as its operational hub and the United States as a core market. That makes the name relevant primarily as a niche services exposure to the broader life-sciences supply chain. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001304161/000165495426000710/pbsv_10k.htm))